QuidelOrtho Corp director Michael Edward L. received several equity-based compensation awards in the form of restricted stock units on June 25, 2026. These awards are structured as premium, converted, and equity grant restricted stock units, each representing the right to receive one share of QuidelOrtho common stock.
The grants were made at a price of $0.00 per unit as compensation rather than open-market purchases. Footnotes explain that one set of restricted stock units will vest on June 25, 2027, and another set vests in four installments of 878, 878, 878, and 879 units on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027, respectively.
The awards were received in lieu of cash payments for certain retainer and Board of Director service-related fees under a deferred compensation program for participating non-employee directors. Vested units will be released according to the director’s elected deferral schedule, emphasizing that these are compensation-related equity grants rather than discretionary stock trades.
QuidelOrtho Corp director Evelyn S. Dilsaver received a grant of 15,532 restricted stock units (RSUs) as equity compensation. Each RSU corresponds to one share of QuidelOrtho common stock and was awarded at no exercise price. All 15,532 RSUs will vest on June 25, 2027, and her reported direct holdings in this RSU award total 15,532 units after the transaction.
QuidelOrtho Corp director Kenneth F. Buechler received equity-based compensation in the form of restricted stock units (RSUs) on June 25, 2026. He was granted 3,661 premium RSUs, 12,204 converted RSUs, and 15,532 equity grant RSUs, each representing one share of common stock.
The RSUs were awarded in lieu of cash retainer and other Board service-related fees under a deferred compensation program for non-employee directors. One RSU equals one share of QuidelOrtho common stock, with vesting noted to occur on June 25, 2027 for certain awards, and additional tranches of 3,051 shares vesting on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027.
QuidelOrtho Corporation is appointing Micah Young as Chief Financial Officer and principal financial officer, effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, who will remain through the transition and then serve as a special advisor.
Young, a seasoned medical technology finance executive and former CFO of Masimo Corporation, will receive a $750,000 annual base salary, an annual target cash bonus equal to 100% of base salary, a $500,000 cash sign-on bonus, and a one-time inducement grant of RSUs valued at $6,500,000 vesting over three years. He is also expected to receive 2027 equity grants valued at $5,000,000, split between time-based RSUs and stock options, along with severance and change-in-control protections consistent with other executives.
Busky will receive an annual base salary of $340,000 for six months after the effective date during the transition, then up to 24 months as special advisor at $100,000 per year, with continued eligibility for 2026 bonus and existing equity vesting terms.
QuidelOrtho Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected all ten director nominees, each receiving over 56 million votes in favor, with several receiving more than 56.6 million votes for and relatively few votes withheld.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 55,716,067 votes for, 1,486,910 against, and 22,228 abstentions, alongside 7,088,721 broker non-votes. In addition, they ratified the appointment of KPMG LLP as independent registered public accounting firm for the 2026 fiscal year, with 64,197,113 votes for, 97,367 against, and 19,446 abstentions.
QuidelOrtho Corp director Kenneth J. Widder reported routine equity compensation activity involving restricted stock units. On June 6, 2026, he acquired 273 and 910 shares of common stock at $0.00 per share through grants/awards.
These shares came from the release and conversion of previously reported restricted stock units into common stock, with 273 and 910 units exercised at a $0.00 conversion price. Footnotes explain that the restricted stock unit release had been deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors and occurred according to his elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D. reported compensation-related equity activity involving restricted stock units and common shares. On June 6, 2026, she exercised a total of 973 restricted stock units at $0.00 per unit, each converting into one share of common stock under the company’s program.
These releases were previously reported awards whose delivery was deferred under QuidelOrtho’s deferred compensation program for non-employee directors. Following these transactions, she held 20,442 shares of common stock directly and 17,353 shares indirectly through an LLC. The filing reflects routine director equity compensation rather than open-market buying or selling.
QuidelOrtho Corp director Kenneth F. Buechler increased his direct stake through equity compensation rather than market buying. On June 6, 2026, he acquired 497 and 1,659 shares of Common Stock at $0.00 per share as grants linked to restricted stock units. These 2,156 shares came from the release and conversion of previously reported restricted stock units under QuidelOrtho's deferred compensation program for participating non-employee directors. Following the transactions, Buechler directly owns 110,906 common shares.
QuidelOrtho Corp director Michael Edward L. reported compensation-related equity activity. He received 1,252 shares of common stock through the release and conversion of restricted stock units on June 6, 2026, at a stated price of $0.00 per share as part of his director compensation. Following these awards and conversions, he holds approximately 29,433 common shares directly. Footnotes explain the restricted stock units were previously reported, each unit represents one common share, and their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors.
QuidelOrtho Corp director Matthew Strobeck increased his direct stake through equity compensation. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at $0.00 per share, previously reported as RSUs.
Following this grant and conversion, he holds 34,604 common shares directly. He also reports indirect positions, including 38,145 shares held by Birchview Fund, LLC, where he has sole voting and dispositive power, and 16,630 shares in UGMA accounts for his children, which he disclaims as beneficially owned.